The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

NCT06851611 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID19, Sars-Cov-2

Interventions

BIOLOGICAL: COVID-19 vaccine, low dose level
BIOLOGICAL: COVID-19 vaccine, high dose level
OTHER: Nasal Drops
OTHER: Nasal Spray

Sponsor

Rokote Laboratories Finland Oy